bearish
Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure
385 Views14 May 2022 18:20
SUMMARY
- Celltrion Inc (068270 KS) reported muted Q1 results, with revenue, operating profit, and net profit declining quarter-over-quarter. Its biosimilar products in the EU are facing price competition.
- Celltrion has recalled its COVID-19 rapid antigen test kits in the U.S. in April, which marks its third such recall in less than two months.
- Celltrion shares plunged 15% since I published bearish insight on the company on March 8. Bear thesis of biosimilar competition still holds good for the company.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Celltrion Siblings Announced Dividends: Trading Based on Past Patterns17 Dec 2022
- Celltrion Group Companies - Sharp Increase in Dividends17 Dec 2022
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing30 Sep 2022
- Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor09 Mar 2022
- FSC Finally Reviews Accounting Fraud Allegations of Celltrion Group After 3 Years of Investigation23 Nov 2021
x